Issue 132

MEP Action Group launches in Europe

In a groundbreaking milestone for psychedelics in Europe, a cross-party MEP Action Group for the Medical Use of Psychedelics was launched at an expert roundtable on 24 May.

The group’s launch results from two years of advocating from campaign groups such as Psychedelic Access and Research European Alliance (PAREA) and Psychedelics EUROPE.

Its key focus is to accelerate the preparation of the regulatory landscape for psychedelic medicines in the EU Single Market.

Further areas of focus will include:

  • Raising awareness of best practices.
  • Promoting discussions around cost-effectiveness.
  • Advocating for a harmonised EU policy and regulatory framework.
  • Fostering drug policies based on scientific evidence and human rights, to remove barriers to scientific research and access.
  • Providing input on key European legislative dossiers such as the EU’s Comprehensive Approach To Mental Health.
READ MORE

FIRST PHASE III TRIAL WITH PSILOCYBIN UNDERWAY

UK-based COMPASS Pathways is conducting the largest ever psilocybin therapy study, with over 800 participants.

Read More

UK GOVERNMENT PLEDGES £650M FOR LIFE SCIENCES

It hopes to support economic growth with new commitments and funding for manufacturing, skills and infrastructure.

Read More

BUSINESS AND INVESTMENT

Seelos Therapeutics releases Q1 2023 financial results. The company reported quarterly revenue of US$808,000.

Cybin announces US$30m stock purchase. The company entered an agreement with Lincoln Park Capital Fund, an institutional investor.

COMPASS co-founder to step down. Ekaterina Malievskaia will remain on the Board of Directors.

On Thursday, 6 July, industry leaders will converge at the iconic British Museum for PSYCH Symposium: London 2023.

Secure your ticket for just £329 + VAT.

TICKET REGISTRATION

SCIENCE AND RESEARCH

Psychedelic medicines spur growth of neural connections. Psilocybin given to mice prompted an immediate and long-lasting increase in connections between neurons.

Psilocybin therapy for cancer patients with depression sees positive results. Sixty-four per cent of patients saw a sustained response, with two-thirds in remission.

Ketamine found to be as effective as electroconvulsive therapy for major depression. The study was the largest to compare the efficacy of both treatments.

5-MeO-DMT modifies innate behaviours in mice. Unlike psilocybin, 5-MeO-DMT did not affect the size of dendritic spines.

REGULATION AND LEGISLATION

Colorado governor signs psychedelics bill into law. The legislation creates a regulatory framework for legal access to psychedelic medicines.

California Senate passes bill to legalise psychedelic medicine. The legislation was approved 21 to 16 and will now head to the Assembly for review.

MPs demand answers as Drugs Minister dodges psilocybin debate. The UK’s Drugs Minister failed to show up for the debate.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Partnership with PSYCH provides the opportunity to engage an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

For more information and to request the PSYCH media kit, please email grace@psych.global.

REQUEST MEDIA KIT

ARTICLES OF INTEREST

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Partnership with PSYCH provides the opportunity to engage an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

For more information and to request the PSYCH media kit, please email grace@psych.global.

REQUEST MEDIA KIT

Met police to stop attending emergency mental health calls. To stop personnel being diverted from fighting crime, they will only attend if there is a threat to life.

IVF patients need more mental health support. A charity surveyed 1,300 fertility patients and found 40% had experienced suicidal feelings.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Partnership with PSYCH provides the opportunity to engage an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

For more information and to request the PSYCH media kit, please email grace@psych.global.

REQUEST MEDIA KIT
Partner with us